Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer

BET bromodomain inhibitors (BBDI) are candidate therapeutic agents in triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limit their potential clinical use. Using CRISPR and small molecule inhibitor screens combined with comprehensive molecular...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Mol Cell
Hoofdauteurs: Shu, Shaokun, Wu, Hua-Jun, Ge, Jennifer Y., Zeid, Rhamy, Harris, Isaac S., Jovanović, Bojana, Murphy, Katherine, Wang, Binbin, Qiu, Xintao, Endress, Jennifer E., Reyes, Jaime, Lim, Klothilda, Font-Tello, Alba, Syamala, Sudeepa, Xiao, Tengfei, Reddy Chilamakuri, Chandra Sekhar, Papachristou, Evangelia K., D’Santos, Clive, Anand, Jayati, Hinohara, Kunihiko, Li, Wei, McDonald, Thomas O., Luoma, Adrienne, Modiste, Rebecca J., Nguyen, Quang-De, Michel, Brittany, Cejas, Paloma, Kadoch, Cigall, Jaffe, Jacob D., Wucherpfennig, Kai W., Qi, Jun, Liu, X. Shirley, Long, Henry, Brown, Myles, Carroll, Jason S., Brugge, Joan S., Bradner, James, Michor, Franziska, Polyak, Kornelia
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306005/
https://ncbi.nlm.nih.gov/pubmed/32416067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molcel.2020.04.027
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items